Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Checked against the public recordLast updated Nov 5, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Sponsor
- Synta Pharmaceuticals Corp.
- Interventions being studied
- Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * confirmed diagnosis of NSCLC * Stage IIIB or IV NSCLC * ECOG Performance Status 0 or 1 * Prior therapy defined as 1 prior systemic therapy for advanced disease * measurable disease * Radiologic evidence of disease progression following most recent prior treatment. * Adequate hematologic, hepatic, renal function Exclusion Criteria: * Active or untreated CNS metastases * Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin * Serious cardiac illness or medical conditions * Pregnant or lactating women * Uncontrolled intercurrent illness
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Synta Pharmaceuticals Investigative SiteTucson, Arizona
- Synta Pharmaceuticals Investigative SiteSanta Monica, California
- Synta Pharmaceuticals Investigative SiteAtlanta, Georgia
- Synta Pharmaceuticals Investigative SiteChicago, Illinois
- Synta Pharmaceutials Investigative SiteBoston, Massachusetts
- Synta Pharmaceuticals Investigative SiteWinston-Salem, North Carolina
- Synta Pharmaceuticals Investigative SiteKettering, Ohio
- Synta Pharmaceuticals Investigative SitePortland, Oregon
- Synta Pharmaceuticals Investigative SiteBrussels
- Synta Pharmaceuticals Investigative SiteJette
- Synta Pharmaceuticals Investigative SiteYvoir
- Synta Pharmaceuticals Investigative SiteBanja Luka
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 5, 2015. Always confirm current availability with the study team.